SAN DIEGO--(BUSINESS WIRE)--Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court in Delaware issued an opinion in the patent litigation brought by Magnolia Medical, Inc. finding that “Kurin is entitled to a judgment of noninfringement of claims 1 and 24 of the #483 patent as a matter of law.”
“It is rewarding to receive the Court’s determination that Kurin does not infringe the ‘483 patent and I appreciate the efforts of our team over the last few years,” said Bob Rogers, CEO of Kurin, Inc. “From the beginning of this case, we felt confident that we would prevail and that the lawsuit was a desperate move by a competitor who could not compete in the marketplace.
“Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of these same two patent claims. This opinion by the Court confirms that even if these patent claims were valid, Kurin does not infringe them. With Magnolia’s case now largely behind us, we can continue to focus on helping hospitals improve clinical outcomes and address the financial challenges posed by blood culture contamination.”
Kurin’s revolutionary 510(k)-cleared approaches to the contaminated blood culture problem are based on elegantly simple, intuitive designs that require no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.
About Kurin, Inc.
Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.
